Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1A1 | P14550 | 18/20 | 0.85 |
| ▸ | AKR1B1 | P15121 | 18/20 | 0.85 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alconil SCHEMBL30661866 | 1.00 | AKR1A1 (0.85) | AKR1A1AKR1B1ITGA4 | |
| Imirestat SCHEMBL30924520 | 0.92 | AKR1A1 (1.00) | AKR1A1AKR1B1ITGA4 | |
| Imirestat SCHEMBL49034 | 0.92 | AKR1A1 (1.00) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL9810968 | 0.91 | ITGA4 (0.73) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL9810984 | 0.89 | AKR1A1 (0.88) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL9810959 | 0.85 | ITGA4 (1.00) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL31195728 | 0.85 | ITGA4 (1.00) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL9810986 | 0.84 | AKR1A1 (0.73) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL20845832 | 0.84 | AKR1A1 (1.00) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL10927385 | 0.84 | AKR1A1 (0.82) | AKR1A1AKR1B1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092566-A1 | Treatment of cancer with aldose reductase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | claimed |
| US-20100016404-A1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2010-01-21 | — | — | US | claimed |
| EP-2032145-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008002678-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-16 | — | — | US | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-12090142-B2 | Combination therapy for the treatment of cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | UNIV CASE WESTERN RESERVE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230054339-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2023-02-23 | — | — | US | disclosed |
| US-20210085650-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-25 | — | — | US | disclosed |
| US-20190183861-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3050593-B1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | UNIV TEXAS (US) | 2018-05-16 | — | — | EP | disclosed |
| US-4600717-A | Aldose reductase inhibitors useful in ophthalmic wound healing | ALCON LABORATORIES, INC. (US) | 1986-07-15 | — | — | US | disclosed |
| US-4540700-A | Treatment of diabetic complications with certain spiro-imidazolidine-diones | ALCON LABORATORIES, INC. (US) | 1985-09-10 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4438272-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1984-03-20 | — | — | US | disclosed |
| US-4436745-A | TETRACYCLIC SPIROHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| EP-0092385-A2 | Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds | ALCON LABORATORIES, INC. (US) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ALDOA, AKR1B1, AKR1A1 | AKR1A1 3/4885AKR1B1 2/4885ITGA4 3899/4885 |
| US-20230054339-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | AKR1B1, AKR1C2, AKR1A1 | AKR1A1 3/4885AKR1B1 1/4885ITGA4 4749/4885 |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1A1 8/4885AKR1B1 9/4885ITGA4 4832/4885 |
| US-20190183861-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | AKR1B1, AKR1C2, AKR1A1 | AKR1A1 3/4885AKR1B1 1/4885ITGA4 4739/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1A1 11/4885AKR1B1 5/4885ITGA4 3315/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1A1 11/4885AKR1B1 5/4885ITGA4 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.